CD36 and hepatocellular carcinoma: Hence, we first investigated CD36+ CAFs in our cohort of resected HCC tissues from patients administered neoadjuvant anti-PD-1 therapy (toripalimab in combination with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma; clinical trial number: NCT03867370).